Osteoporosis International

, Volume 22, Issue 2, pp 559–565

Efficacy and safety of bazedoxifene in postmenopausal Asian women


    • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
  • K.-S. Tsai
    • National Taiwan University Hospital
  • G. S. Kim
    • Asan Medical Center
  • Y. Wu
    • Beijing Hospital
  • P. Vincendon
    • Pfizer Inc
  • A. A. Chines
    • Pfizer Inc
  • G. D. Constantine
    • Pfizer Inc
Original Article

DOI: 10.1007/s00198-010-1259-5

Cite this article as:
Xu, L., Tsai, K., Kim, G.S. et al. Osteoporos Int (2011) 22: 559. doi:10.1007/s00198-010-1259-5



This 6-month study examined the efficacy and safety of bazedoxifene 20 mg in postmenopausal Asian women. Bazedoxifene showed statistically significant improvements over placebo in bone mineral density at all skeletal sites evaluated. Bazedoxifene significantly reduced bone turnover and had favorable effects on lipid parameters. Bazedoxifene was safe and well tolerated.


This 6-month, randomized, double-blind, placebo-controlled phase 3 study conducted in China, Korea, and Taiwan evaluated the efficacy and safety of bazedoxifene in postmenopausal Asian women.


Generally, healthy postmenopausal Asian women (N = 487; mean age, 57.2 years; mean lumbar spine bone mineral density [BMD], −1.1) were randomized to daily therapy with bazedoxifene 20 mg or placebo; all subjects received daily supplemental calcium carbonate 600 mg. The changes from baseline in BMD at the lumbar spine (primary end point) and at other skeletal sites, bone turnover markers, and lipid parameters were evaluated at 6 months. Safety assessments included adverse event (AE) reporting and physical/gynecologic examination.


At 6 months, women who received bazedoxifene 20 mg had significantly greater BMD compared with those receiving placebo at the lumbar spine (0.41% vs −0.32%, P < 0.01), femoral neck (−0.08% vs −0.69%, P = 0.014), trochanter (0.50% vs −0.23%, P = 0.010), and total hip (−0.03% vs −0.77%, P < 0.001), respectively. Bazedoxifene 20 mg was also associated with significant differences from placebo in median percent reductions from baseline in serum C-telopeptide (−21.8%, P < 0.001) and osteocalcin (−12.9%, P < 0.001) levels and total (−5.0%, P < 0.001) and low-density lipoprotein cholesterol (−9.5%, P < 0.001) levels. The incidence of AEs was not different between subjects treated with bazedoxifene and those who received placebo.


Bazedoxifene was generally safe and effective in preventing bone loss in this short-term study of postmenopausal Asian women.


BazedoxifeneBone mineral densityOsteoporosisPostmenopausalPreventionSERMs

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010